Position your portfolio before the wall of “dumb money” floods in…

This “Tiny” Biotech Stock CouldBe Massive for Early Investors…

Cybin Announces Final Approval for Listing On NYSE American your email below to get your free early investor report on Cybin, Inc.

If you’re looking for early investment opportunities in the promising medical psychedelic research space then keep your eyes on Cybin Inc.

  • 13 psychedelic related patents filed…
  • 50 different proprietary psychedelic molecules developed
  • 4 promising active drug programs in the pipeline
  • And much more!

Meet the CEO…A 30 year veteran in the healthcare sector, Doug Drysdale has built and turned-around 4 pharmaceutical companies, completed 15 corporate acquisitions, and has raised $4 billion of both public and private capital.

And according to Drysdale, Cybin Inc. (NEO:CYBN)(OTCQB:CLXPF) disrupting one of the largest fields in modern medicine is a key component of their growth strategy…

We are focused on addressing the mental health crisis and transforming the treatment landscape.

– Doug Drysdale
, Cybin CEO

Don’t expect Cybin Inc. (NEO:CYBN)(OTCQB:CLXPF) to remain “tiny” once the news about their revolutionary medical breakthroughs goes mainstream.

Investors looking for early opportunities in psychedelic medicine should move quickly on Cybin Inc. (NEO:CYBN)(OTCQB:CLXPF) and establish
a position before the wall of retail and institutional money starts moving in on the opportunity.

Be part of the FutureEnter your email below to get your free early investor report on Cybin, Inc.


Company Overview

  • We are focused on addressing the mental health crisis and transforming the treatment landscape. To do that, we are combining technology and our scientific expertise to pair novel psychedelic molecules with controllable drug delivery systems, aimed at improving outcomes for patients.
  • C$88M raised to date. Well-funded to progress clinical trials, M&A and IP strategies.
  • 4 active drug programs targeting Major Depressive Disorder, Alcohol Use Disorder and Therapy Resistant Psychiatric Disorders (CYB001, CYB003, CYB004, CYB005).
  • Phase II approval to commence clinical trial on CYB001 which is targeting Major Depressive Disorder.
  • 13 patent filings and growing which cover Novel psychedelic compounds, Integration of delivery platforms, Methods of use in psychiatric indications, Drug discovery pipeline of modified and novel ergolines, tryptamines and phenethylamines.
  • 50+ pre-clinical studies completed and progressing lead programs toward FDA IND filings
  • Experienced leadership and scientific team that has previously successfully brought multiple drugs to market, collectively involved in 37 exits and overseen 60+ IND programs with the FDA

We’re on a mission to
revolutionize mental healthcare.

View Corporate Presentation


Be part of the FutureEnter your email below to get your free early investor report on Cybin, Inc.



This communication is a advertisement. Tips4Traders is a brand name of IRPub LLC and MediaPub Holdings, its owners, directors, officers, employees, affiliates, agents and assigns (collectively the “Publisher”) is often paid by one or more of the profiled companies or a third party to disseminate these types of communications. In this case, the Publisher has been compensated by Cybin Corp. (OTC: CLXPF | NEO:CYBN) to conduct public investor awareness, distribution and investor education marketing for a period of 45-60 days. Cybin Corp. has paid the Publisher the equivalent of One-Hundred Thousand USD to produce and disseminate this and other similar articles and certain related banner advertisements. This compensation should be viewed as a major conflict with the Publisher’s ability to provide unbiased information or opinion.


Readers should beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you receive this communication, which has the potential to adversely affect share prices. Frequently companies profiled in our articles experience a large increase in share trading volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in share trading volume and share price may likely occur.


This communication is not, and should not be construed to be, an offer to sell or a solicitation of an offer to buy any security.


Neither this communication nor the Publisher purport to provide a complete analysis of any company or its financial position. This communication is based on information generally available to the public and on an interview conducted with the company’s CEO, and does not contain any material, non public information. The information on which it is based is believed to be reliable. Nevertheless, the Publisher does not guarantee the accuracy or completeness of the information. Further, the information in this communication is not updated after publication and may become inaccurate or outdated. No reliance should be placed on the price or statistics information and no responsibility or liability is accepted for any error or inaccuracy. Any statements made should not be taken as an endorsement of analyst views.


The Publisher is not, and does not purport to be, a broker-dealer or registered investment adviser or a financial adviser. The Publisher has no access to non-public information about publicly traded companies. The information provided is general and impersonal, and is not tailored to any particular individual’s financial situation or investment objective(s) and this communication is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor or a personal recommendation to deal or invest in any particular company or product. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the advertised company’s SEC, SEDAR and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk. Past performance does not guarantee future results.


This communication contains forward-looking statements, including statements regarding expected continual growth of the featured companies and/or industry. Statements in this communication that look forward in time, which include everything other than historical information, are based on assumptions and estimates by our content providers and involve risks and uncertainties that may affect the profiled company’s actual results of operations. These statements involve known and unknown risks, uncertainties and other important factors that could cause the actual results and performance to differ materially from any future results or performance expressed or implied in the forward-looking statements. These risks, uncertainties and other factors include, among others: the success of the profiled company’s operations; the size and growth of the market for the company’s products and services; the company’s ability to fund its capital requirements in the near term and long term; pricing pressures; changes in business strategy, practices or customer relationships; general worldwide economic and business conditions; currency exchange and interest rate fluctuations; government, statutory, regulatory or administrative initiatives affecting the company’s business.


By reading this communication, you acknowledge that you have read and understand this disclaimer in full, and agree and accept that the Publisher provides no warranty in respect of the communication or the profiled company and accepts no liability whatsoever. You acknowledge and accept this disclaimer and that, to the greatest extent permitted under applicable law, you release and hold harmless the Publisher from any and all liability, damages, injury and adverse consequences arising from your use of this communication. You further agree that you are solely responsible for any financial outcome related to or arising from your investment decisions.


By reading this communication you agree that you have reviewed and fully agree to the Terms of Use found here  and acknowledge that you have reviewed the Disclaimer found here: If you do not agree to the Terms of Use, please contact to discontinue receiving email communications.


All trademarks used in this communication are the property of their respective trademark holders. Other than, the Publisher is not affiliated, connected, or associated with, and the communication is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Publisher to any rights in any third-party trademarks other than


All of the content found on this page was authored by our 3rd party affiliate partner. TipsforTraders, IRPub LLC, and our affiliates are not responsible for the content or accuracy of this article.

TipsForTraders, IRPub LLC, DO NOT hold any position in the stock(s) and/or financial instrument(s) mentioned in the above piece. We have been paid to produce this piece by the Company or companies mentioned above.